How might the MORPHO trial of gilteritinib impact clinical practice?
The AML Hub spoke to Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK at ASH 2023. We asked, How might the MORPHO trial of gilteritinib impact clinical practice? Hosted on Acast. ...
8 Apr 20247min
Risk stratification and guidelines in AML management
The AML Hub was pleased to speak to Gail Roboz, Weill Cornell Medicine, New York, US, and Naval Daver, MD Anderson Cancer Center, Houston, US. We asked about risk stratification and guidelines in acut...
8 Jan 202411min
How are new fludarabine conditioning combinations impacting transplant outcomes?
During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessalonik...
22 Apr 20226min
Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatmen...
10 Juli 20216min
Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, Should pre-transplant minimal residual disease (MRD) be use...
25 Juni 202113min
Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Gert Ossenkoppele, Amsterdam UMC, Amsterdam, NL. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment i...
23 Juni 20215min
Can HMA maintenance therapy improve eligibility for HSCT?
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT? Ravand...
17 Mars 20215min
ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Andrew Wei, The Alfred Hospital, Melbourne, AU, and Natasha S. Anstee, The Alfred Hospital & Mo...
2 Feb 202116min
